SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?


To: keokalani'nui who wrote (334)1/23/2005 4:13:29 PM
From: DewDiligence_on_SI  Read Replies (1) | Respond to of 671
 
>>All eyes are on Alnylam I suspect.<<

The private firm, Acuity Pharma, will likely have the first test case for an RNAi therapeutic, and it will be in the indication that is best tailored for this approach: age-related macular degeneration (AMD). I’ll be looking to get into ALNY (assuming the price is right) if there are some compelling data from Acuity.

Talk biotech at www.tinyurl.com/zaqn